ResMed Inc. (RMD)

From the record

ResMed Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2026-08-17) (its current reports).

From the record

ResMed Inc.'s 10 filed years say what it did: revenue went from $2.1 billion in fiscal 2017 to $5.7 billion in fiscal 2026, up 11.8% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-06-30, ResMed Inc.'s diluted share count shrank about 0.3% a year, and dividends and buybacks returned about 42% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 29 sales (29 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-13 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-06-30, ResMed Inc. earned about 23 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 38 cents per dollar of everything the company owns. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count shrank 0.9% over the year (the filed statements).

From the record

ResMed Inc.'s standing among 109 graded names in its industry family: revenue of $5.7 billion in fiscal 2026 ranks in the top 7% by size; a net margin of 26.9% ranks in the top 3%; revenue growth of 10.2% a year over the last 3 filed years ranks in the bottom 44% (its annual reports).

From the record

ResMed Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Farrell, Michael J. (Chairman and CEO, as filed), filing under that title since 2013-03-05, 13.7 years (top 7% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 7.7 years (top 20%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 32%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

ResMed Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $1.5 billion against debt of $399 million leaves 11.9% of its assets as net cash, top 48% of its family; cash from operations less capital spending is 29.2% of revenue (top 3%); a gross margin of 61.1% (bottom 50%); research spending of 6.7% of revenue (bottom 32%) (its annual report).

From the record

ResMed Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 10.2% a year over the last three filed years against 11.8% over all 10, slowing (bottom 42% of its family); the newest year grew 9.9% (bottom 40%); research spending grew 9.6% a year (top 36%); capital spending grew 9.3% a year (top 37%) (its annual reports). ResMed Inc. reported 2 lines of business in fiscal 2026: Sleep and Breathing Health at $5.0 billion (88%), Residential Care Software at $676 million (12%); 2 of 2 grew against the year before (its annual report).

From the record

ResMed Inc.'s newest year against its own record: revenue of $5.7 billion in fiscal 2026 came in 0.5% below the $5.7 billion its prior three years' pace pointed to (top 42% of its family); net income of $1.5 billion against a prior three-year average of $1.1 billion (top 40%); a net margin of 26.9% against 23.4% before (bottom 36%) (its annual reports).